Viking Therapeutics announced plans to advance its oral dual GLP‑1/GIP receptor agonist VK‑2735 into a Phase III obesity program, targeting a Q3 2026 start. VK‑2735 is being developed in both subcutaneous and oral formulations, with the company positioning the candidate for metabolic indications including obesity. The move places Viking among developers racing to deliver oral incretin combinations and reflects demand for oral alternatives to injectable GLP‑1 medicines. Viking said the Phase III design and timelines will be disclosed as the program is finalized and that regulatory interactions remain part of the next steps.